What is the required concentration of venetoclax/venetoclax?

Venetoclax (Venetoclax) has become a breakthrough in the treatment of leukemias with large inter-individual pharmacokinetic differences. Here, a rapid, sensitive, and reliable UPLC-MS/MS method was developed and validated for the quantification of venetoclax in plasma. The peak plasma concentration (Cmax) of venetoclax in Chinese acute myeloid leukemia (AML) patients was 2966.0±1595.0ng/mL, and the trough concentration (Cmin) was 1018.0±729.4ng/mL. Furthermore, Cmax and Cmin were positively correlated with AST levels. Furthermore, Cmax was significantly higher in elderly patients.

There is no fixed standard for the drug concentration of Venetoclax because it is affected by many factors, including the time of taking the drug, the amount of dosage, and individual physical differences. According to several publications, venetoclax plasma concentrations in humans (including healthy volunteers, patients with chronic lymphocytic leukemia, and patients with small lymphocytic lymphoma) vary between 30 and 4000 ng/mL at different dose levels (100-600 mg), indicating that the calibration curve is capable of measuring venetoclax concentrations in human plasma by including peak and trough concentrations.

The original drug of Venekra has been launched in China and has been included in Class B medical insurance. The price of 100mg*14 tablets per box may be around 2,000 RMB, while the Turkish version of the original drug sold overseas, with the specification of 100mg*112 tablets, costs more than 10,000 RMB per box (the price may fluctuate due to the exchange rate). There are also cheaper generic drugs of Venacla sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 100mg*120 tablets produced by a Bangladesh pharmaceutical factory is more than 4,000 yuan per box (the price may fluctuate due to the exchange rate).